2 mg · vegan · gluten-free · 30 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
CJC-1295 (no DAC) is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is designed to mimic the pulsatile release of GHRH, stimulating the pituitary gland to release growth hormone (GH). This peptide is researched for its potential role in supporting healthy aging processes.
By binding to GHRH receptors, CJC-1295 (no DAC) stimulates the anterior pituitary gland to secrete GH in a pulsatile manner, similar to natural physiological rhythms. This increased GH release can lead to downstream effects including increased IGF-1 production, impacting cellular repair, regeneration, and metabolic functions over time.
Adults looking to address premature ageing, low energy, cellular stress. Particularly relevant for people who prefer a targeted single ingredient and who have ruled out an underlying condition that needs medical care first.
Pregnant or nursing women without clinician oversight. People on prescription medication affecting the same pathway should consult a doctor before combining. Side effects are uncommon at recommended doses but mild GI upset can occur when starting.
C · C · emerging-to-moderate human evidence for healthy ageing and cellular longevity
SacredBod's longer take on CJC-1295 (no DAC) — context the structured blocks above don't capture.
CJC-1295 (no DAC) is a peptide supplement used to support healthy ageing and cellular longevity. GHRH analogue researched for GH pulses. It is available in capsule form and dosed for adults in India and internationally. As a peptide-tradition entry in the SacredBod catalog, it is positioned as a single-ingredient option that can be used on its own or layered into a broader protocol. CJC-1295 (no DAC) works through the mechanisms characteristic of its class — see the mechanism and research sections for detail. It primarily acts on the mitochondria, cells, telomeres, and effects are dose-dependent, typically becoming measurable within 8-12 weeks for longevity markers. Consistency matters more than dose size for this category.
CJC-1295 (no DAC) carries an evidence grade of C in the SacredBod catalog, reflecting emerging human evidence for healthy ageing and cellular longevity. GHRH analogue researched for GH pulses. Benefits are cumulative rather than immediate, typically becoming noticeable within 8-12 weeks for longevity markers, and individual response varies.
A typical dose is 2 mg, taken with food, usually in the morning. Start at the lower end, assess tolerance, and stay consistent; more is not automatically better.
Pregnant or nursing women without clinician oversight. People on prescription medication affecting the same pathway should consult a doctor before combining. Side effects are uncommon at recommended doses but mild GI upset can occur when starting.
Adults looking to address premature ageing, low energy, cellular stress. Particularly relevant for people who prefer a targeted single ingredient and who have ruled out an underlying condition that needs medical care first.
As part of the Peptide category, CJC-1295 (no DAC) can be used on its own or layered into a broader protocol — see the Goes with panel for evidence-aligned pairings.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
Request received.
We'll route this to a clinician familiar with peptide protocols. Expect a reply within about 48 hours.
How's your experience? We read every note.
